Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Inhibitory Effects of Probenecid on Pharmacokinetics of Tenofovir Disoproxil Fumarate and Emtricitabine for On-Demand HIV Pre-Exposure Prophylaxis.

Liu SN, Gufford BT, Lu JBL, Bushman LR, Anderson PL, Bergstrom RF, Desta Z, Gupta SK.

Clin Pharmacol Ther. 2019 Nov 1. doi: 10.1002/cpt.1714. [Epub ahead of print]

PMID:
31675437
2.

Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study.

Marins LMS, Torres TS, Leite IDC, Moreira RI, Luz PM, Hoagland B, Kallas EG, Madruga JV, Liu AY, Anderson PL, Grinsztejn B, Veloso VG.

PLoS One. 2019 Aug 20;14(8):e0221281. doi: 10.1371/journal.pone.0221281. eCollection 2019.

3.

Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial.

Keller MJ, Wood L, Billingsley JM, Ray LL, Goymer J, Sinclair S, McGinn AP, Marzinke MA, Frank B, Srinivasan S, Liu C, Atrio JM, Espinoza L, Mugo N, Spiegel HML, Anderson PL, Fredricks DN, Hendrix CW, Marrazzo J, Bosinger SE, Herold BC.

Lancet HIV. 2019 Aug;6(8):e498-e508. doi: 10.1016/S2352-3018(19)30145-6. Epub 2019 Jul 15.

PMID:
31320290
4.

Cascade of Antiretroviral Therapy Adherence in Virologically Suppressed Persons Living with HIV.

Castillo-Mancilla JR, Coyle RP, Coleman SS, Morrow M, Gardner EM, Zheng JH, Ellison L, Bushman LR, Kiser JJ, MaWhinney S, Anderson PL.

AIDS Res Hum Retroviruses. 2019 Jul 30. doi: 10.1089/AID.2019.0024. [Epub ahead of print]

PMID:
31204866
5.

What Can Urine Tell Us About Medication Adherence?

Anderson PL.

EClinicalMedicine. 2018 Sep 15;2-3:5-6. doi: 10.1016/j.eclinm.2018.09.003. eCollection 2018 Aug-Sep. No abstract available.

6.

Changes in Bone Mass After Discontinuation of Pre-Exposure Prophylaxis (PrEP) with Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.

Havens PL, Perumean-Chaney SE, Patki A, Cofield SS, Wilson CM, Liu N, Anderson PL, Landovitz RJ, Kapogiannis BG, Hosek SG, Mulligan K.

Clin Infect Dis. 2019 Jun 8. pii: ciz486. doi: 10.1093/cid/ciz486. [Epub ahead of print]

PMID:
31179503
7.

Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project.

Spinelli MA, Glidden DV, Anderson PL, Gandhi M, McMahan VM, Defechereux P, Schechter M, Veloso VG, Chariyalertsak S, Guanira JV, Bekker LG, Buchbinder SP, Grant RM.

AIDS Res Hum Retroviruses. 2019 Sep;35(9):788-793. doi: 10.1089/AID.2018.0297. Epub 2019 Jun 19.

PMID:
31119944
8.

Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing.

Spinelli MA, Glidden DV, Anderson PL, Gandhi M, Cohen S, Vittinghoff E, Coleman ME, Scott H, Bacon O, Elion R, Kolber MA, Buchbinder SP, Liu AY.

J Acquir Immune Defic Syndr. 2019 Jun 1;81(2):158-162. doi: 10.1097/QAI.0000000000002005.

PMID:
31095005
9.

Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate.

Brooks KM, Ibrahim ME, Castillo-Mancilla JR, MaWhinney S, Alexander K, Tilden S, Kerr BJ, Ellison L, McHugh C, Bushman LR, Kiser JJ, Hosek S, Huhn GD, Anderson PL.

J Antimicrob Chemother. 2019 Aug 1;74(8):2352-2359. doi: 10.1093/jac/dkz187.

PMID:
31093649
10.

Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir.

Brooks KM, Castillo-Mancilla JR, Blum J, Huntley R, MaWhinney S, Alexander K, Kerr BJ, Ellison L, Bushman LR, MacBrayne CE, Anderson PL, Kiser JJ.

J Antimicrob Chemother. 2019 Aug 1;74(8):2360-2364. doi: 10.1093/jac/dkz184.

PMID:
31081036
11.

When a Colonic Metal Stent Is Left in for Too Long: A Devastating Coloenteric Fistula from Stent Erosion and Migration.

Lee H, Prabhakaran K, Krowsoski L, Anderson PL, Lombardo G.

Am Surg. 2019 Mar 1;85(3):e182-e184. No abstract available.

PMID:
30947804
12.

Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV.

Morrow M, MaWhinney S, Coyle RP, Coleman SS, Gardner EM, Zheng JH, Ellison L, Bushman LR, Kiser JJ, Anderson PL, Castillo-Mancilla JR.

J Infect Dis. 2019 Jul 19;220(4):635-642. doi: 10.1093/infdis/jiz144.

PMID:
30942881
13.

Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles.

Goodman-Meza D, Beymer MR, Kofron RM, Amico KR, Psaros C, Bushman LR, Anderson PL, Bolan R, Jordan WC, Rooney JF, Wohl AR, Landovitz RJ.

AIDS Care. 2019 Oct;31(10):1228-1233. doi: 10.1080/09540121.2019.1595523. Epub 2019 Mar 20.

PMID:
30894013
14.

Predictors of Long-Term HIV Pre-exposure Prophylaxis Adherence After Study Participation in Men Who Have Sex With Men.

Hoenigl M, Hassan A, Moore DJ, Anderson PL, Corado K, Dubé MP, Ellorin EE, Blumenthal J, Morris SR; California Collaborative Treatment Group (CCTG) 601 Team.

J Acquir Immune Defic Syndr. 2019 Jun 1;81(2):166-174. doi: 10.1097/QAI.0000000000002003.

PMID:
30865175
15.

A Hand-Held Non-Robotic Surgical Tool With a Wrist and an Elbow.

Riojas KE, Anderson PL, Lathrop RA, Herrell SD, Rucker DC, Webster Iii RJ.

IEEE Trans Biomed Eng. 2019 Nov;66(11):3176-3184. doi: 10.1109/TBME.2019.2901751. Epub 2019 Feb 26.

PMID:
30835205
16.

Engagement in Mental Health Care is Associated with Higher Cumulative Drug Exposure and Adherence to Antiretroviral Therapy.

Coyle RP, Schneck CD, Morrow M, Coleman SS, Gardner EM, Zheng JH, Ellison L, Bushman LR, Kiser JJ, Mawhinney S, Anderson PL, Castillo-Mancilla JR.

AIDS Behav. 2019 Feb 23. doi: 10.1007/s10461-019-02441-8. [Epub ahead of print]

PMID:
30798457
17.

Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy.

Frasca K, Morrow M, Coyle RP, Coleman SS, Ellison L, Bushman LR, Kiser JJ, Zheng JH, Mawhinney S, Anderson PL, Castillo-Mancilla J.

J Antimicrob Chemother. 2019 May 1;74(5):1395-1401. doi: 10.1093/jac/dky559.

PMID:
30668713
18.

A meta-analytic examination of attrition in virtual reality exposure therapy for anxiety disorders.

Benbow AA, Anderson PL.

J Anxiety Disord. 2019 Jan;61:18-26. doi: 10.1016/j.janxdis.2018.06.006. Epub 2018 Jun 21.

PMID:
30646997
19.

Self-initiated continuation of and adherence to HIV pre-exposure prophylaxis (PrEP) after PrEP demonstration project roll-off in men who have sex with men: associations with risky decision making, impulsivity/disinhibition, and sensation seeking.

Hoenigl M, Morgan E, Franklin D, Anderson PL, Pasipanodya E, Dawson M, Hanashiro M, Ellorin EE, Blumenthal J, Heaton R, Moore DJ, Morris SR; California Collaborative Treatment Group (CCTG) 601 Team.

J Neurovirol. 2019 Jun;25(3):324-330. doi: 10.1007/s13365-018-0716-3. Epub 2019 Jan 7.

PMID:
30617849
20.

The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM.

McGowan I, Wilkin T, Landovitz RJ, Wu C, Chen Y, Marzinke MA, Hendrix CW, Richardson P, Eshleman SH, Andrade A, Chege W, Anderson PL, McCauley M, Farley J, Mayer KH, Anton P, Brand RM, Cranston RD, Gulick R.

AIDS. 2019 Feb 1;33(2):237-246. doi: 10.1097/QAD.0000000000002038.

PMID:
30557160
21.

Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report.

Cohen SE, Sachdev D, Lee SA, Scheer S, Bacon O, Chen MJ, Okochi H, Anderson PL, Kearney MF, Coffey S, Scott H, Grant RM, Havlir D, Gandhi M.

Lancet HIV. 2018 Nov 29. pii: S2352-3018(18)30288-1. doi: 10.1016/S2352-3018(18)30288-1. [Epub ahead of print]

PMID:
30503324
22.

Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1.

Hoenigl M, Jain S, Moore D, Collins D, Sun X, Anderson PL, Corado K, Blumenthal JS, Daar ES, Milam J, Dubé MP, Morris S; California Collaborative Treatment Group 595 Team.

Emerg Infect Dis. 2018 Dec;24(12). doi: 10.3201/eid2412.180400.

23.

Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048.

Liu AY, Zhang J, Anderson PL, Wagner T, Pan Z, Peda M, Gomez K, Beamer M, Jacobson C, Strizki J, Dezzutti CS, Piper JM; MTN-028 Protocol Team for the Microbicide Trials Network.

Clin Infect Dis. 2019 Mar 19;68(7):1129-1135. doi: 10.1093/cid/ciy652.

24.

Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings.

Hoesley CJ, Chen BA, Anderson PL, Dezzutti CS, Strizki J, Sprinkle C, Heard F, Bauermeister J, Hall W, Jacobson C, Berthiaume J, Mayo A, Gundacker H, Richardson-Harman N, Piper J; Microbicide Trials Network 027 Study Team.

Clin Infect Dis. 2019 Mar 19;68(7):1136-1143. doi: 10.1093/cid/ciy653.

25.

Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.

Havens PL, Tamhane A, Stephensen CB, Schuster GU, Gordon CM, Liu N, Wilson CM, Hosek SG, Anderson PL, Kapogiannis BG, Mulligan K.

AIDS Res Hum Retroviruses. 2019 Feb;35(2):123-128. doi: 10.1089/AID.2018.0096. Epub 2018 Nov 5.

PMID:
30280906
26.

Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study.

Liu AY, Vittinghoff E, von Felten P, Rivet Amico K, Anderson PL, Lester R, Andrew E, Estes I, Serrano P, Brothers J, Buchbinder S, Hosek S, Fuchs JD.

Clin Infect Dis. 2019 May 30;68(12):2010-2017. doi: 10.1093/cid/ciy810.

27.

Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring.

Koss CA, Liu AY, Castillo-Mancilla J, Bacchetti P, McHugh C, Kuncze K, Morrow M, Louie A, Seifert S, Okochi H, MaWhinney S, Gandhi M, Anderson PL.

AIDS. 2018 Sep 24;32(15):2189-2194. doi: 10.1097/QAD.0000000000001935.

PMID:
30212404
28.

Pharmacologic-Based Methods of Adherence Assessment in HIV Prevention.

Brooks KM, Anderson PL.

Clin Pharmacol Ther. 2018 Dec;104(6):1056-1059. doi: 10.1002/cpt.1201. Epub 2018 Sep 4. No abstract available.

PMID:
30178462
29.

Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections.

Castillo-Mancilla JR, Morrow M, Coyle RP, Coleman SS, Gardner EM, Zheng JH, Ellison L, Bushman LR, Kiser JJ, Mawhinney S, Anderson PL.

Clin Infect Dis. 2019 Apr 8;68(8):1335-1342. doi: 10.1093/cid/ciy708.

30.

Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing.

Innes S, van der Laan L, Anderson PL, Cotton M, Denti P.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e00761-18. doi: 10.1128/AAC.00761-18. Print 2018 Nov.

31.

Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis.

Chua CYX, Jain P, Ballerini A, Bruno G, Hood RL, Gupte M, Gao S, Di Trani N, Susnjar A, Shelton K, Bushman LR, Folci M, Filgueira CS, Marzinke MA, Anderson PL, Hu M, Nehete P, Arduino RC, Sastry JK, Grattoni A.

J Control Release. 2018 Sep 28;286:315-325. doi: 10.1016/j.jconrel.2018.08.010. Epub 2018 Aug 6.

32.

In-capillary microextraction for direct mass spectrometry analysis of biological samples.

Ren Y, Zhang W, Lin Z, Bushman LR, Anderson PL, Ouyang Z.

Talanta. 2018 Nov 1;189:451-457. doi: 10.1016/j.talanta.2018.07.027. Epub 2018 Jul 11.

33.

Cryopreservation of human mucosal tissues.

Hughes SM, Ferre AL, Yandura SE, Shetler C, Baker CAR, Calienes F, Levy CN, Astronomo RD, Shu Z, Lentz GM, Fialkow M, Kirby AC, McElrath MJ, Sinclair E, Rohan LC, Anderson PL, Shacklett BL, Dezzutti CS, Gao D, Hladik F.

PLoS One. 2018 Jul 30;13(7):e0200653. doi: 10.1371/journal.pone.0200653. eCollection 2018.

34.

Deterioration rates in Virtual Reality Therapy: An individual patient data level meta-analysis.

Fernández-Álvarez J, Rozental A, Carlbring P, Colombo D, Riva G, Anderson PL, Baños RM, Benbow AA, Bouchard S, Bretón-López JM, Cárdenas G, Difede J, Emmelkamp P, García-Palacios A, Guillén V, Hoffman H, Kampann I, Moldovan R, Mühlberger A, North M, Pauli P, Peñate Castro W, Quero S, Tortella-Feliu M, Wyka K, Botella C.

J Anxiety Disord. 2019 Jan;61:3-17. doi: 10.1016/j.janxdis.2018.06.005. Epub 2018 Jul 17.

PMID:
30057346
35.

Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor.

Ibrahim ME, Brooks KM, Castillo-Mancilla JR, McHugh C, Morrow M, Brothers J, MaWhinney S, Hosek S, Huhn G, Anderson PL.

AIDS Res Hum Retroviruses. 2018 Oct;34(10):835-837. doi: 10.1089/AID.2018.0081. Epub 2018 Sep 5.

36.

Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.

Pyra M, Anderson PL, Hendrix CW, Heffron R, Mugwanya K, Haberer JE, Thomas KK, Celum C, Donnell D, Marzinke MA, Bukusi EA, Mugo NR, Asiimwe S, Katabira E, Baeten JM; Partners Demonstration Study Team.

AIDS. 2018 Aug 24;32(13):1891-1898. doi: 10.1097/QAD.0000000000001922.

37.

CYP2D6 Genotype Phenotype Discordance Due to Drug-Drug Interaction.

Monte AA, West K, McDaniel KT, Flaten HK, Saben J, Shelton S, Abdelmawla F, Bushman LR, Williamson K, Abbott D, Anderson PL.

Clin Pharmacol Ther. 2018 Nov;104(5):933-939. doi: 10.1002/cpt.1135. Epub 2018 Jul 25.

38.

Pharmacokinetic and Pharmacodynamic Properties of Metronidazole in Pediatric Patients With Acute Appendicitis: A Prospective Study.

Child J, Chen X, Mistry RD, Somme S, MacBrayne C, Anderson PL, Jones RN, Parker SK.

J Pediatric Infect Dis Soc. 2019 Sep 25;8(4):297-302. doi: 10.1093/jpids/piy040.

PMID:
29788329
39.

Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.

MacBrayne CE, Marks KM, Fierer DS, Naggie S, Chung RT, Hughes MD, Kim AY, Peters MG, Brainard DM, Seifert SM, Castillo-Mancilla JR, Bushman LR, Anderson PL, Kiser JJ.

J Antimicrob Chemother. 2018 Aug 1;73(8):2112-2119. doi: 10.1093/jac/dky146.

40.

Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.

Grinsztejn B, Hoagland B, Moreira RI, Kallas EG, Madruga JV, Goulart S, Leite IC, Freitas L, Martins LMS, Torres TS, Vasconcelos R, De Boni RB, Anderson PL, Liu A, Luz PM, Veloso VG; PrEP Brasil Study Team.

Lancet HIV. 2018 Mar;5(3):e136-e145. doi: 10.1016/S2352-3018(18)30008-0. Epub 2018 Feb 18.

PMID:
29467098
41.

Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study.

Grant RM, Mannheimer S, Hughes JP, Hirsch-Moverman Y, Loquere A, Chitwarakorn A, Curlin ME, Li M, Amico KR, Hendrix CW, Anderson PL, Dye BJ, Marzinke MA, Piwowar-Manning E, McKinstry L, Elharrar V, Stirratt M, Rooney JF, Eshleman SH, McNicholl JM, van Griensven F, Holtz TH.

Clin Infect Dis. 2018 May 17;66(11):1712-1721. doi: 10.1093/cid/cix1086.

42.

Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine.

Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.

Clin Infect Dis. 2018 Jul 18;67(3):411-419. doi: 10.1093/cid/ciy083.

43.

Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial.

Baxi SM, Vittinghoff E, Bacchetti P, Huang Y, Chillag K, Wiegand R, Anderson PL, Grant R, Greenblatt RM, Buchbinder S, Gandhi M, Liu AY.

PLoS One. 2018 Jan 9;13(1):e0190118. doi: 10.1371/journal.pone.0190118. eCollection 2018.

44.

Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy.

Seifert SM, Castillo-Mancilla JR, Erlandson K, Morrow M, Gandhi M, Kuncze K, Horng H, Zheng JH, Bushman LR, Kiser JJ, MaWhinney S, Anderson PL.

J Acquir Immune Defic Syndr. 2018 Mar 1;77(3):295-298. doi: 10.1097/QAI.0000000000001596.

45.

Continuum Reconfigurable Parallel Robots for Surgery: Shape Sensing and State Estimation with Uncertainty.

Anderson PL, Mahoney AW, Webster RJ 3rd.

IEEE Robot Autom Lett. 2017 Jul;2(3):1617-1624. doi: 10.1109/LRA.2017.2678606. Epub 2017 Mar 6.

46.

Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis.

Markowitz M, Grossman H, Anderson PL, Grant R, Gandhi M, Horng H, Mohri H.

J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):e104-e106. doi: 10.1097/QAI.0000000000001534. No abstract available.

47.

Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.

Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C, Wagner T, Campbell K, Morrow M, Ibrahim M, Buchbinder S, Bushman LR, Kiser JJ, MaWhinney S.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01710-17. doi: 10.1128/AAC.01710-17. Print 2018 Jan.

48.

Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.

Koss CA, Hosek SG, Bacchetti P, Anderson PL, Liu AY, Horng H, Benet LZ, Kuncze K, Louie A, Saberi P, Wilson CM, Gandhi M.

Clin Infect Dis. 2018 Jan 6;66(2):213-219. doi: 10.1093/cid/cix755.

49.

Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.

Tang EC, Vittinghoff E, Anderson PL, Cohen SE, Doblecki-Lewis S, Bacon O, Coleman ME, Buchbinder SP, Chege W, Kolber MA, Elion R, Shlipak M, Liu AY.

J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):193-198. doi: 10.1097/QAI.0000000000001566.

50.

Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.

Bekker LG, Roux S, Sebastien E, Yola N, Amico KR, Hughes JP, Marzinke MA, Hendrix CW, Anderson PL, Elharrar V, Stirratt M, Rooney JF, Piwowar-Manning E, Eshleman SH, McKinstry L, Li M, Dye BJ, Grant RM; HPTN 067 (ADAPT) study team.

Lancet HIV. 2018 Feb;5(2):e68-e78. doi: 10.1016/S2352-3018(17)30156-X. Epub 2017 Oct 3.

Supplemental Content

Loading ...
Support Center